Puriblood Medical Co., Ltd.

Taipei Exchange 6847.TWO

Puriblood Medical Co., Ltd. Receivables for the year ending December 31, 2023: USD 273.72 K

Puriblood Medical Co., Ltd. Receivables is USD 273.72 K for the year ending December 31, 2023, a -54.57% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • Puriblood Medical Co., Ltd. Receivables for the year ending December 31, 2022 was USD 602.44 K, a 105.09% change year over year.
  • Puriblood Medical Co., Ltd. Receivables for the year ending December 31, 2021 was USD 293.75 K, a -45.91% change year over year.
  • Puriblood Medical Co., Ltd. Receivables for the year ending December 31, 2020 was USD 543.09 K, a 775.30% change year over year.
  • Puriblood Medical Co., Ltd. Receivables for the year ending December 31, 2019 was USD 62.05 K.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
Taipei Exchange: 6847.TWO

Puriblood Medical Co., Ltd.

CEO Dr. Luke Chen
IPO Date Nov. 5, 2021
Location
Headquarters No.11, Gongye East 9th Road
Employees 42
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Puriblood Medical Co., Ltd. develops and sells blood cell separation products in Taiwan. The company offers leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. It also offers Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. In addition, the company develops P-Tex Technology, which is composed by bio-inspired molecular formula – zwitterionic copolymer structure. Puriblood Medical Co., Ltd. was founded in 2016 and is based in Hsinchu City, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email